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Receptor for advanced glycation end products (RAGE) is a multiligand receptor belonging to the 
immunoglobulin superfamily and plays a crucial role in the development of many human diseases such as 
neurodegenerative diseases, diabetes, cardiovascular diseases and cancer.1 RAGE is involved in a number of 
cell processes such as neuroinflammation, apoptosis, proliferation and autophagy, and therefore it is of 
considerable interest as a promising drug target for innovative therapeutic approaches. It consists of an 
extracellular region, a short hydrophobic transmembrane spanning region, and a highly charged amino acid 
cytoplasmatic tail. The extracellular region contains a signal peptide, followed by one N-terminal V-type 
immunoglobulin domain  and two C-type (C1 and C2) immunoglobulin domains.2 RAGE is able to interact with 
a large number of pro-inflammatory and regulatory molecules, such as advanced glycation end-products 
(AGEs), quinolinic acid, beta amyloid (Aβ), high mobility group box 1 (HMGB1), S100/calgranulin family 
proteins.3,4 However, due to the structural heterogeneity of these endogenous ligands, little is known about 
the key pharmacophore elements for ligand-RAGE interaction and the specific mode of binding. 
 
 
On these grounds, we aimed at designing new small molecules able to bind the VC1 extracellular domains of 
RAGE, in order to clarify the structural features that account for RAGE affinity and activation, and to identify 
new drug-like compounds. Following a process of structural simplification of known pyrazole-5-carboxamide 
RAGE ligands,1 we planned a set of novel derivatives characterized by a variously functionalized 3-
cyclopropyl-4-phenoxy-1H-pyrazole scaffold (Figure 1). The design and synthesis of the new putative RAGE 
ligands will be presented and discussed, together with the results of their in vitro screening by means of a 
surface plasmon resonance (SPR)-based assay to estimate their binding ability to the RAGE extracellular 
domain.  
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Figure 1. Schematic depiction of RAGE structure and general structure of the new pyrazole-based RAGE ligands. 
